AXLRx Book a callCommission

Big Pharma · Rare Disease

Sanofi — Rare Disease

Sanofi across Rare Disease: the full competitive set, and the 3 AXLRx reports mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.

Commission a Sanofi report

By therapy area

Therapy area All areas ImmunologyRare DiseasePulmonology

Market All United States

AXLRx reports featuring Sanofi — Rare Disease

CI · Rare Disease · CI Team · Launch Lead · Market Access US Gaucher Disease Competitive Intelligence Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot. US · In-Market · Read report → CI · Rare Disease · CI Team · Launch Lead · Market Access US Pompe Disease Competitive Intelligence Two next-generation ERTs are moving to displace alglucosidase alfa in US late-onset Pompe disease. Avalglucosidase alfa and cipaglucosidase alfa plus miglustat now define the competitive set. US · In-Market · Read report → CI · Rare Disease · CI Team · Launch Lead · Market Access US Fabry Disease Competitive Intelligence Pegunigalsidase now challenges Fabrazyme's two-decade lead in US Fabry disease. Two IV enzyme replacement therapies meet an oral chaperone only ~35–50% of patients can take. US · In-Market · Read report →